看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。' D" z1 P. v, i- d1 L8 b$ H
( b* v- q7 I9 J2 Q
) y3 B! T* I# \! d1 f% E" s2 c5 |. \
Currently available feasibility data for possible combination strategies.
6 b3 M4 M# n+ d————————————————————————————————
8 X+ m) F$ L& E+ L. qCombination Feasibility according to preliminary data M0 u- |* Z9 q. R- C) |; i5 o
——————————————————————————————————
! D6 y2 C" [( qBevacizumab + sorafenib Yes, reduced dose
- f$ Z/ V& q4 ~2 \Bevacizumab + sunitinib† No
$ h* X" m3 ]) ^Bevacizumab + temsirolimus Yes
) G) J G4 }0 UBevacizumab + everolimus Yes M3 n7 }# @9 l. ?' ]3 y/ V
Sorafenib + sunitinib ? . X, A4 K. Z! n9 U' a3 Y. B6 p
Sorafenib + temsirolimus Yes, reduced dose - { L( t% a; p! v$ b ?
Sorafenib + everolimus Yes, reduced dose
* [& v6 I0 g& d% J2 x N2 V/ iSunitinib + temsirolimus† No
/ @# \' {/ l/ ^, V7 \Sunitinib + everolimus ?
3 j$ Z1 Y+ C% H6 r: CTemsirolimus + everolimus ?
8 h9 ~. c8 [5 l! c2 k- o————————————————————3 x* X" e% e6 ]: x3 ~; S/ b0 @
†Led to US FDA warning.
# J: I7 W4 \: a% _- n$ i) t?: As yet unattempted combination.2 q# D4 f- |3 ?" c& N9 m5 N
|
显身卡
